Study drug mix for unresectable gallbladder cancer
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests a combination of cancer medicines (gemcitabine plus albumin-paclitaxel) along with immune therapy (sintilimab) and a blood-vessel–targeting drug (bevacizumab). It’s for people with gallbladder cancer that can’t be removed by surgery, to see if the treatment controls the cancer and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18–75 years old and sign consent before any study steps.
- Your gallbladder cancer must be confirmed by pathology testing (biopsy/cytology).
- You must not have had prior whole-body (systemic) anti-cancer treatment like chemotherapy or immunotherapy.
- You need at least one measurable tumor seen on scans, and you must be fit enough for treatment (ECOG 0–1).
- Your blood, liver, kidney, and clotting test results must meet specific safety cutoffs.
- If you can become pregnant, you must have a negative pregnancy test and use reliable birth control during treatment and for 120 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (gemcitabine, nab-paclitaxel, lenvatinib, and tislelizumab) for people with advanced bile duct or gallbladder cancer that cannot be removed by surgery and has not been treated before.
This trial tests a new approach for gallbladder cancer that has grown into nearby areas but hasn't spread far. It combines a drug called AK112 (a type of immunotherapy that helps your immune system fight cancer) with standard chemotherapy and an anti-angiogenesis drug (GAP) before surgery, in the hope of shrinking the tumor enough to allow successful surgery.
This trial is testing a combination of four drugs (gemcitabine, cisplatin, nab-paclitaxel, and durvalumab) for people with gallbladder cancer that has spread or cannot be removed by surgery. The goal is to see if this drug combination helps shrink or control the cancer.
This trial tests a combination of three drugs for bile duct cancer that cannot be removed by surgery: sintilimab (an immunotherapy that helps your immune system fight cancer), bevacizumab (a drug that blocks blood vessel growth to tumors), and a standard chemotherapy called AG (gemcitabine and capecitabine). The goal is to see if this combination can help shrink or control the cancer as a first treatment option.
This trial tests a combination of two chemotherapy drugs (gemcitabine and nab-paclitaxel) with two immunotherapy drugs (iparomlimab and tuvorilimab) for people with advanced gallbladder cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink the cancer or slow its growth.
This Phase 2 trial tests a targeted treatment (GEMOX) given after gallbladder cancer surgery. It uses a blood test that looks for cancer-related DNA to monitor recurrence and guide care, aiming to improve outcomes for people with higher-risk disease.
Hear when a new Gallbladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.